Dong-Hua Yang Selected Research

Member 2 Subfamily G ATP Binding Cassette Transporter

1/2021	OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance.
11/2020	Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dong-Hua Yang Research Topics

Disease

75	Neoplasms (Cancer) 03/2024 - 05/2002
7	Carcinoma (Carcinomatosis) 01/2020 - 10/2002
6	Neoplasm Metastasis (Metastasis) 04/2023 - 10/2002
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 06/2014
6	Hepatocellular Carcinoma (Hepatoma) 05/2017 - 04/2000
5	Lung Neoplasms (Lung Cancer) 04/2023 - 01/2017
4	Breast Neoplasms (Breast Cancer) 12/2021 - 10/2012
4	Squamous Cell Carcinoma of Head and Neck 01/2021 - 12/2013
3	Colonic Neoplasms (Colon Cancer) 07/2021 - 08/2020
2	Hematologic Neoplasms (Hematological Malignancy) 03/2024 - 05/2015
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2023 - 01/2022
2	Myocardial Ischemia (Ischemic Heart Diseases) 06/2022 - 03/2017
2	Triple Negative Breast Neoplasms 12/2021 - 01/2020
2	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 01/2013
2	Adenocarcinoma 07/2017 - 01/2016
2	Carcinogenesis 01/2013 - 06/2004
2	Cysts 12/2003 - 10/2002
1	Residual Neoplasm 03/2024
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2023
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2023
1	Prostatic Neoplasms (Prostate Cancer) 01/2023
1	Primary Myelofibrosis (Myelosclerosis) 12/2022
1	Thrombocytopenia (Thrombopenia) 12/2022
1	Polycythemia (Erythrocytosis) 12/2022
1	Reperfusion Injury 06/2022
1	Myocardial Infarction 06/2022
1	Pathologic Complete Response 01/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022
1	Liver Neoplasms (Liver Cancer) 04/2021
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2021

Drug/Important Bio-Agent (IBA)

14	Proteins (Proteins, Gene)FDA Link 01/2023 - 10/2002
10	ATP-Binding Cassette Transporters (ABC Transporters)IBA 07/2020 - 01/2016
8	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 07/2021 - 04/2011
6	Adenosine Triphosphate (ATP)IBA 07/2020 - 01/2017
6	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2013
5	Doxorubicin (Adriamycin)FDA LinkGeneric 07/2021 - 05/2014
4	Cisplatin (Platino)FDA LinkGeneric 12/2022 - 12/2013
4	Paclitaxel (Taxol)FDA LinkGeneric 12/2022 - 01/2017
4	Topotecan (Hycamtin)FDA LinkGeneric 01/2021 - 06/2014
4	Antineoplastic Agents (Antineoplastics)IBA 07/2020 - 01/2018
3	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2022
3	oridoninIBA 01/2020 - 01/2016
3	ErbB Receptors (EGF Receptor)IBA 01/2019 - 01/2013
2	AntigensIBA 03/2024 - 01/2023
2	Chimeric Antigen ReceptorsIBA 03/2024 - 01/2023
2	Phosphotransferases (Kinase)IBA 12/2022 - 01/2019
2	EnzymesIBA 01/2022 - 11/2018
2	venetoclaxIBA 01/2022 - 02/2020
2	9 alpha,11 alpha,15 alpha- trihydroxy- 16- phenoxy- 17,18,19,20- tetranorprosta- 4,5,13- trienoic acid (TPT)IBA 01/2021 - 01/2020
2	Member 2 Subfamily G ATP Binding Cassette TransporterIBA 01/2021 - 11/2020
2	Tyrosine Kinase InhibitorsIBA 01/2020 - 01/2018
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2018 - 07/2017
2	Messenger RNA (mRNA)IBA 05/2017 - 06/2004
2	CholesterolIBA 09/2015 - 01/2013
2	SterolsIBA 09/2015 - 01/2013
2	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 08/2012 - 04/2011
2	Phosphodiesterase 5 InhibitorsIBA 08/2012 - 04/2011
2	Single-Chain AntibodiesIBA 05/2010 - 01/2001
2	Laminin (Merosin)IBA 10/2002 - 05/2002
2	CollagenIBA 10/2002 - 05/2002
1	Cyclin D1IBA 01/2023
1	Circular RNAIBA 01/2023
1	Mitochondrial RNAIBA 01/2023
1	LipidsIBA 01/2023
1	AllergensIBA 01/2023
1	Macrophage Colony-Stimulating FactorIBA 12/2022
1	Docetaxel (Taxotere)FDA Link 12/2022
1	Taxoids (Taxanes)IBA 12/2022
1	Interleukin-1 Receptor-Associated KinasesIBA 12/2022
1	11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA 12/2022
1	Carboplatin (JM8)FDA LinkGeneric 12/2022
1	Janus Kinase 2IBA 12/2022
1	geniposideIBA 06/2022
1	InflammasomesIBA 06/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2022
1	Amino Acids FDA Link 01/2022
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022
1	Type I DNA Topoisomerases (Topoisomerase I)IBA 12/2021
1	evodiamineIBA 12/2021
1	CurcuminIBA 07/2021
1	Phosphates (Orthophosphate)IBA 04/2021
1	TubulinIBA 04/2021
1	Proteolysis Targeting ChimeraIBA 01/2021
1	Hypnotics and Sedatives (Sedatives)IBA 01/2021
1	SurvivinIBA 01/2021
1	Interleukin-10 (Interleukin 10)IBA 01/2021
1	Tramadol (K315)FDA LinkGeneric 01/2021
1	Dexmedetomidine FDA Link 01/2021
1	Tripartite Motif ProteinsIBA 01/2021
1	p38 Mitogen-Activated Protein KinasesIBA 01/2021
1	alectinibIBA 01/2021
1	Therapeutic UsesIBA 01/2021

Therapy/Procedure

20	Drug Therapy (Chemotherapy) 01/2023 - 04/2011
19	Therapeutics 03/2024 - 12/2013
4	Immunotherapy 01/2023 - 11/2018
2	Chinese Traditional Medicine (Traditional Chinese Medicine) 04/2023 - 03/2017
2	Combination Drug Therapy (Combination Chemotherapy) 01/2020 - 01/2017
1	Castration 01/2023
1	Aftercare (After-Treatment) 01/2022
1	Transplantation 01/2021